Immunological Strategies to Fight Skin Cancer

B. Berman, MD, PhD; O. A. Perez, MD; D. Zell, MD


Skin Therapy Letter. 2006;11(5):1-7. 

In This Article


Dose-related serious toxicities have limited IL-2 studies in melanoma patients, and low-dose IL-2 therapy has produced disappointing clinical response rates.[38] When high-dose, 100,000 units/kg, intravenous, recombinant IL-2 was examined in 47 patients with metastatic malignant melanoma, up to 20% achieved objective responses; however, three patients developed myocardial infarction and one patient died during therapy.[39] IL-2-based biochemotherapy (IL-2, IFN-α-2b, cisplatin, dacarbazine, and vinblastine) has shown a response rate of 48%. It appears that this combination is statistically superior to either IL-2 or chemotherapy alone.[40] Results of ongoing trials may clarify the true value of IL-2 in combination chemotherapy. ( Table 3 ).


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.